surmount-1 trial tirzepatide obesity without diabetes Tirzepatide as Compared with Semaglutide
Description
Those seeking steadier blood sugar control with proven long-term data may prefer Ozempic (semaglutide)
Clinical trial data shows this dose produces approximately 20 percent average weight loss over 72 weeks
If approved, theyll issue a prescription
00656-2/asset/38c98550-9ec2-44e8-ba6a-dbb815075666/main.assets/gr1_lrg.jpg)
Some of the GLP-1s in the study have not yet been approved specifically for obesity treatment
Published online February 1, 2024
We also advise on lifestyle adjustments, such as eating smaller meals and avoiding greasy foods, to help minimize gastrointestinal discomfort
